Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The Million Women Study: design and characteristics of the study population. The Million Women Study Collaborative Group.

Million Women Study Collaborative Group..

Breast Cancer Res. 1999;1(1):73-80. Epub 1999 Aug 19.

3.

Estrogen replacement therapy in patients with early breast cancer.

Natrajan PK, Gambrell RD Jr.

Am J Obstet Gynecol. 2002 Aug;187(2):289-94; discussion 294-5.

PMID:
12193914
5.

Hormonal therapy for menopause and breast-cancer risk by histological type: a cohort study and meta-analysis.

Reeves GK, Beral V, Green J, Gathani T, Bull D; Million Women Study Collaborators..

Lancet Oncol. 2006 Nov;7(11):910-8.

PMID:
17081916
6.

Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.

Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D.

BMJ. 1989 Dec 16;299(6714):1487-91.

7.

Breast cancer histological classification: agreement between the Office for National Statistics and the National Health Service Breast Screening Programme.

Gathani T, Bull D, Green J, Reeves G, Beral V; Million Women Study Collaborators..

Breast Cancer Res. 2005;7(6):R1090-6. Epub 2005 Nov 9.

8.

Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis.

Hunt K, Vessey M, McPherson K.

Br J Obstet Gynaecol. 1990 Dec;97(12):1080-6.

PMID:
2126197
9.

The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer.

Sellers TA, Mink PJ, Cerhan JR, Zheng W, Anderson KE, Kushi LH, Folsom AR.

Ann Intern Med. 1997 Dec 1;127(11):973-80.

PMID:
9412302
10.

Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy.

Dimitrakakis C, Jones RA, Liu A, Bondy CA.

Menopause. 2004 Sep-Oct;11(5):531-5.

PMID:
15356405
11.
13.

Post-menopausal hormone replacement therapy (cont'd): risk-benefit balance in the hot seat.

[No authors listed]

Prescrire Int. 2004 Jun;13(71):106-9.

PMID:
15233153
14.

Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.

Health Quality Ontario..

Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.

15.

Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography.

Laya MB, Larson EB, Taplin SH, White E.

J Natl Cancer Inst. 1996 May 15;88(10):643-9.

PMID:
8627640
16.

Risk of venous thromboembolism in users of hormone replacement therapy.

Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S.

Lancet. 1996 Oct 12;348(9033):977-80.

PMID:
8855852
17.

Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy.

Renard F, Vankrunkelsven P, Van Eycken L, Henau K, Boniol M, Autier P.

Ann Oncol. 2010 Dec;21(12):2356-60. doi: 10.1093/annonc/mdq240. Epub 2010 May 3.

PMID:
20439342
19.

Endometrial cancer and hormone-replacement therapy in the Million Women Study.

Beral V, Bull D, Reeves G; Million Women Study Collaborators..

Lancet. 2005 Apr 30-May 6;365(9470):1543-51.

PMID:
15866308
20.

Use of HRT and the subsequent risk of cancer.

Beral V, Banks E, Reeves G, Appleby P.

J Epidemiol Biostat. 1999;4(3):191-210; discussion 210-5. Review.

PMID:
10695959

Supplemental Content

Support Center